Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Instituto Nacional de Cancerologia de Mexico | OTHER |
| Amsterdam UMC, location VUmc | OTHER |
| Pontificia Universidad Catolica de Chile | OTHER |
| Vall d'Hebron Institute of Oncology |
Not provided
Not provided
Not provided
Not provided
The study uses a case-control design that examines the differences in types of exposures between cases defined with a pathological confirmation of GC diagnosis, and controls, defined as patients to whom a gastroscopy was indicated and confirmed absent of GC i
GC is associated to several known risk factors. Epidemiological and molecular features of GCs can vary widely. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori), Epstein Barr virus infection, dietary factors and others. These factors can influence GC outcomes. There is little knowledge regarding how these risk factors are associated with GC in CELAC and EU populations.
The primary objectives of this study are to:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cases | Patients with a pathological confirmation of GC diagnosis | ||
| Control | Patients with confirmed absent of GC |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Exposure to a variety of potential sources of GC risk factors | The ratio of the odds of exposure vs. odds of no exposure to a variety of potential sources of GC risk factors in cases vs. controls. | 3 years |
Not provided
Not provided
Cases
Inclusion criteria
Exclusion criteria:
Controls
Inclusion criteria
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Instituto Alexander Fleming | Buenos Aires | C1426NZ | Argentina | |||
| Pontificia Universidad Católica de Chile |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35692051 | Derived | van Schooten TS, Derks S, Jimenez-Marti E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O'Connor JM, Esteso F, Farres J, Mas JM, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T; members of LEGACy consortium. The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. BMC Cancer. 2022 Jun 13;22(1):646. doi: 10.1186/s12885-022-09689-9. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013274 | Stomach Neoplasms |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| OTHER |
| INSTITUTO ALEXANDER FLEMING | UNKNOWN |
| Hospital Central del IPS | OTHER |
| IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto | OTHER |
Not provided
Not provided
Not provided
| Santiago |
| 8331150 |
| Chile |
| Instituto Nacional de Cancerología | Mexico City | 01480 | Mexico |
| VU Medical Centre | Amsterdam | 1081 | Netherlands |
| GenPat | Asunción | Paraguay |
| Institute of Pathology and Immunology of University of Porto | Porto | 4200 135 | Portugal |
| Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (VHIO) | Barcelona | 08035 | Spain |
| Hospital Clínico Universitario de Valencia | Valencia | 46010 | Spain |
| D005767 | Gastrointestinal Diseases |
| D013272 | Stomach Diseases |